Clinical Trial Update: A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of ipatasertib with fluoropyrimidine plus oxaliplatin in advanced/metastatic gastric or gastroesophageal junction cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• fluoropyrimidine (fluoropyrimidine)
• ipatasertib (ipatasertib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-02-17